Patients with diabetes are at increased risk of developing hepatocellular carcinoma (HCC) and have a poorer prognosis as compared to non-diabetics when HCC occurs. Diabetics with non-HCC cancers are at higher risk of toxicity related to systemic therapy, but data on HCC are lacking.
Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma / Di Costanzo, Giovan Giuseppe; Tortora, Raffaella; Morisco, Filomena; Addario, Luigi; Guarino, Maria; Cordone, Gabriella; Falco, Luigia; Caporaso, Nicola. - In: TARGETED ONCOLOGY. - ISSN 1776-2596. - 12:1(2017), pp. 61-67-67. [10.1007/s11523-016-0454-5]
Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma
MORISCO, FILOMENA;GUARINO, MARIA;CAPORASO, NICOLA
2017
Abstract
Patients with diabetes are at increased risk of developing hepatocellular carcinoma (HCC) and have a poorer prognosis as compared to non-diabetics when HCC occurs. Diabetics with non-HCC cancers are at higher risk of toxicity related to systemic therapy, but data on HCC are lacking.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
diabete e hcc.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Accesso privato/ristretto
Dimensione
527.8 kB
Formato
Adobe PDF
|
527.8 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
